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Abstract
Background: Diseases of the posterior segment of the eye, including age-related macular degeneration (AMD), have recently
been recognised as the leading or second leading cause of blindness in several African countries. However, prevalence of AMD
alone has not been assessed. We hypothesized that AMD is an important cause of visual impairment among elderly people in
Nakuru, Kenya, and therefore sought to assess the prevalence and predictors of AMD in a diverse adult Kenyan population.
Methods and Findings: In a population-based cross-sectional survey in the Nakuru District of Kenya, 100 clusters of 50 people
50 y of age or older were selected by probability-proportional-to-size sampling between 26 January 2007 and 11 November 2008.
Households within clusters were selected through compact segment sampling. All participants underwent a standardised
interview and comprehensive eye examination, including dilated slit lamp examination by an ophthalmologist and digital retinal
photography. Images were graded for the presence and severity of AMD lesions following a modified version of the International
Classification and Grading System for Age-Related Maculopathy. Comparison was made between slit lamp biomicroscopy (SLB)
and photographic grading. Of 4,381 participants, fundus photographs were gradable for 3,304 persons (75.4%), and SLB was
completed for 4,312 (98%). Early and late AMD prevalence were 11.2% and 1.2%, respectively, among participants graded on
images. Prevalence of AMD by SLB was 6.7% and 0.7% for early and late AMD, respectively. SLB underdiagnosed AMD relative to
photographic grading by a factor of 1.7. After controlling for age, women had a higher prevalence of early AMD thanmen (odds
ratio 1.5; 95% CI, 1.2–1.9). Overall prevalence rose significantly with each decade of age. We estimate that, in Kenya, 283,900 to
362,800 people 50 y and older have early AMD and 25,200 to 50,500 have late AMD, based on population estimates in 2007.
Conclusions: AMD is an important cause of visual impairment and blindness in Kenya. Greater availability of low vision
services and ophthalmologist training in diagnosis and treatment of AMD would be appropriate next steps.
Please see later in the article for the Editors’ Summary.
Citation: Mathenge W, Bastawrous A, Peto T, Leung I, Foster A, et al. (2013) Prevalence of Age-Related Macular Degeneration in Nakuru, Kenya: A Cross-Sectional
Population-Based Study. PLoS Med 10(2): e1001393. doi:10.1371/journal.pmed.1001393
Academic Editor: Susan Lewallen, Kilimanjaro Centre for Community Ophthalmology, Tanzania, United Republic of
Received June 20, 2012; Accepted January 9, 2013; Published February 19, 2013
Copyright:  2013 Mathenge et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by funding from: British Council for the Prevention of Blindness (BCPB) and the Fred Hollows Foundation (to WM). AB is
funded by a Medical Research Council and Fight for Sight Fellowship and is in receipt of an International Glaucoma Association Award Fellowship and funding
from BCPB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: AMD, age-related macular degeneration; SES, socioeconomic status; SLB, slit lamp biomicroscopy.
* E-mail: Andrew.bastawrous@lshtm.ac.uk
Introduction
In the latest estimates of global blindness and visual impairment
undertaken by the World Health Organization, in 2010, age-
related macular degeneration (AMD) is the third most common
cause of blindness worldwide behind cataracts and glaucoma [1].
It has remained an important cause of blindness globally since the
last World Health Organization survey in 2002, in which it was
identified as the leading cause of blindness in high-income
countries [2]. As the global population ages, AMD is likely to
increase in importance. Currently, no curative treatment exists.
The recent promise of anti–vascular endothelial growth factor
treatments is unlikely to offset the growth of AMD globally, as
these treatments are only useful in exudative AMD and are not
currently widely accessible outside of high-income countries.
Nutritional interventions can reduce the progression of certain
subtypes of early AMD [3]; however, protective levels of required
vitamins and minerals are difficult to obtain in a healthy diet, and
the cost of supplementation is prohibitive for many who could
potentially benefit [4].
The majority of data on AMD available globally is from
population-based studies undertaken in white and Asian popula-
tions [5–13], and few data are from peoples of African descent.
The data that do exist for individuals of African descent are largely
from studies undertaken in populations living outside of the
African continent [14,15]. It is presumed that AMD is rare in
Africans; however, in the last 10 y, African population-based
studies have suggested that posterior segment eye diseases are
highly prevalent, and this group of disorders, which includes
AMD, diabetic retinopathy, and glaucoma, has been highlighted
as either the leading or second leading cause of blindness in
surveys undertaken in Cameroon [16], Tanzania [17], Kenya
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[18], Rwanda [19], Zanzibar [20], and Guinea [21]. These
studies, however, did not assess AMD as a specific entity and did
not use digital retinal photography. Moreover, comparative data
for whites and Africans living in the same geographical area
(Baltimore, Maryland, US) have suggested differing predispositions
towards AMD, with possible genetically protective factors for
AMD progression in individuals of African descent compared to
their white counterparts [22]. Population-based evidence for
African populations living in Africa on the prevalence of the
disease, and of the risk factors for AMD, is therefore important.
The purpose of this study was to estimate the prevalence and
risk factors for AMD in the age group 50 y and over in an African
population in Nakuru District, Kenya, using digital retinal
photography and slit lamp biomicroscopy (SLB). Nakuru District
is within the Rift Valley Province in Kenya, with a population of
nearly 10 million, approximately one-quarter of the Kenyan
population. Nakuru is diverse in its ethnic mix (all 42 tribes present
in Kenya represented within the district), range of socioeconomic
activity, and urban/rural mix.
Methods
Ethics Statement
Ethical approval was granted by the London School of Hygiene
& Tropical Medicine Ethics Committee and by the Kenya
Medical Research Institute. Approval was also granted by the Rift
Valley Provincial Medical Officer and the Nakuru District
Medical Officer of Health. Written approval was sought from
the administrative head in each cluster, usually the village chief.
All participants gave written or verbal consent to participate.
People requiring medical treatment were referred to the appro-
priate centre.
Sampling Strategy and Recruitment
The study fieldwork was carried out in two phases, from 11
January to 2 June 2007 and from 8 April to 11 November 2008.
Recent census data for Kenya were not available [23], and
therefore election roll lists that were renewed in 2006 in
preparation for the 2007 general elections were used as the
sampling frame for this survey. 100 clusters were selected with a
probability proportional to the size of the population. A cluster was
defined as the area served by a polling station.
Households were selected within clusters using a modified
compact segment sampling method [24]. Each cluster was divided
into segments so that each segment included approximately 50
people aged $50 y. One segment was selected at random, and all
eligible people were included sequentially until 50 had been
examined. Location data including GPS coordinates of houses and
mobile phone contacts were taken to allow follow-up of all those
examined.
This sample size was sufficient to estimate a prevalence of AMD
of 3.0% among those aged 50+ y, with a required precision of
0.5%, 95% confidence, a design effect to account for clustering of
1.5, and a response rate of 90% (Epi Info 6.04, US Centers for
Disease Control and Prevention).
Ophthalmic and General Examination
Suitable predetermined examination sites were selected, on the
recommendation of the village leader, with close proximity to the
cluster and to electricity supply (mains or generator).
Visual Acuity
The presenting visual acuity was defined as the number of
letters read correctly without glasses if the participant did not have
glasses or with glasses if they had them. Testing was done on each
eye separately at 4 m using a reduced LogMAR tumbling ‘‘E’’
chart [25] in a well-illuminated area, as described elsewhere [26].
Fundus Photography
The participants had two nonstereoscopic digital 45u fundus
photographs taken per eye by an ophthalmic clinical officer using
a TRC-NW6S Non-Mydriatic Retinal Camera with a ten-
megapixel Nikon D80 camera (Topcon). One image was centred
on the optic disc, while the other was centred on the macula. The
digital images were stored on hard disc, backed up on an external
drive, and one copy saved on CD was forwarded to the Retinal
Grading Centre at Moorfields Eye Hospital Reading Centre in
London for grading and confirming the clinical diagnosis of
posterior segment disease.
Image Grading
The senior grader (I. L.) graded all images. All images were first
categorised for quality as excellent, good, fair, borderline, or
ungradable. All questionable lesions and all eyes classified as
having late-stage AMD were adjudicated by the Moorfields Eye
Hospital Reading Centre clinician (T. P.). Any lesions considered
to be due to other causes such as myopia and inflammatory disease
were not graded for AMD, and these were also verified by T. P.
The adjudicator also graded 5% of randomly selected images to
ensure quality control. Data were entered into Excel and checked
for consistency by a data monitor. Those with images were
classified as ‘‘image group’’ for further analysis.
Retinal Examination
SLB was performed after pharmacological dilatation with guttae
tropicamide 1% using a 90 diopter lens. Assessment was inclusive
of the macula, the retinal vasculature, and the peripheral retina.
The view of the retina was recorded as clear, hazy, or no view.
The macula was examined for presence of drusen, hypo- or hyper-
pigmentation, dry AMD or geographic atrophy (GA), and
neovascular changes. Any other pathologies of the retina or
vitreous, e.g., retinal detachments or vitreous haemorrhages, were
also noted, and a description given. Those with slit lamp
examination were classified as ‘‘SLB group’’.
Definitions Used
A modified version of the International Classification and
Grading System for Age-Related Maculopathy and Age-Related
Macular Degeneration [27] was used for image grading. Drusen
were categorised based on size, uniformity of colour, and margins.
Based on these, patients were classified into hard or soft drusen
categories. Small drusen, less than 63 mm, were considered to be
hard. Large drusen with a uniform density, sharp margins, and a
nodular surface texture were placed in the soft distinct category,
whereas those without sharp margins were classified as indistinct.
Where end-stage disease was apparent, patients were classified as
having geographic atrophy if there were well-demarcated regions
with diameters in excess of 175 mm, within which large choridal
vessels were clearly visible, owing to the atrophy of the overlying
choriocapillaris and retinal pigment epithelium. Neovascular
AMD was graded as present when exudative features, such as
serous fluid, haemorrhage, lipid exudates, or fibrosis, were seen to
be originating primarily from the subretinal and pigmentepithelial
tissue layers.
SLB grading of AMD was as follows: (1) drusen present:
presence of discrete whitish-yellow spots at the macula area; (2)
pigmentary changes present: presence of increased pigment or
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hyperpigmentation or sharply demarcated areas of depigmenta-
tion or hypopigmentation of the retinal pigment epithelium; (3) dry
AMD or geographic atrophy: atrophy of the retinal pigment
epithelium, with visible underlying choroidal vessels; (4) wet or
neovascular AMD: presence of retinal pigment epithelium
detachment, subretinal or subpigment epithelial neovasculariza-
tion, or fibrous scar tissue, haemorrhages, or exudates; (5) no
AMD: none of the features described above were present; (6)
cannot assess: the retina could not be adequately visualised for
grading. Case definitions were based on the eye with more severe
status if both eyes were gradable, and on the gradable eye if only
one eye was gradable (n=37).
Detailed interviews were undertaken in the local language
covering demographic details, information on risk factors,
socioeconomic status (SES), and full past medical history. SES
was evaluated using a continuous asset score that was produced for
each participant using a scoring system derived through principal
component analysis in an earlier study in this setting [28,29]. The
scale included assessment of 17 context-specific asset items owned
by the household, including different types of furniture, electrical
equipment, cattle, and vehicles. Information was collected on five
household characteristics, including the building material of the
floor, roof, and walls; type of toilet; and the number of rooms. The
score was divided into quartiles based on the distribution across all
the study participants, to derive a measure of relative SES.
Weight, height, waist and hip circumference, blood pressure,
and random cholesterol and glucose blood levels were also
measured. ‘‘Mother tongue’’ was used as a measure of tribal
affiliation.
Data Handling and Statistical Analysis Methods
Data entry. Data were double-entered into a specially
developed dataset (EpiData Entry, version 2.1). Consistency
checks were performed each evening, and inconsistencies correct-
ed the same day.
Data analysis. The prevalence of AMD was estimated, and
the ‘‘svy’’ command in Stata was used with a design effect of 1.5 in
order to take into account the cluster sampling survey method-
ology when calculating confidence intervals around the prevalence
estimates.
Statistical analyses were undertaken using Stata. Logistic
regression analyses were produced to assess the univariate
associations between potential risk factors (age, gender, SES,
tribal origin, hypertension, diabetes, angina, cholesterol level, body
mass index, waist:hip ratio, previous cataract surgery, smoking and
alcohol consumption, education, and urban versus rural) and
prevalent AMD. Multivariable logistic regression models were
developed through stepwise selection, with variables retained at
the p,0.05 level. These analyses were restricted to cases defined
from the image group data, since definite disease status was
available only for this group.
The data for individuals with both SLB and retinal images were
used to calculate a correction factor (if needed) to apply to the SLB
group to estimate the overall prevalence of AMD for Nakuru.
Estimated numbers of individuals within Kenya with AMD were
extrapolated from population data from the US Census Bureau
International Data Base (http://www.census.gov/population/
international/data/idb/country.php) by applying age- and sex-
specific prevalence estimates for the Kenyan population.
Results
There were 5,010 eligible individuals identified for this study.
Of these, 4,414 participants underwent examination, giving a
response rate of 88.1%, and 4,381 had full ophthalmic examina-
tion; 33 participants were not included in the ophthalmic analysis
because of missing data as a consequence of equipment failure. Of
the non-respondents, 584 (98%) were away working or visiting
family outside the cluster location, and 12 (2%) refused to
participate; none were excluded as a result of inability to
communicate. The socio-demographic characteristics of the
participant group are described in earlier publications [30]. Out
of the 4,381 individuals who had ophthalmic examinations in the
Nakuru study, 4,312 (98.4%) were successfully screened for AMD
by SLB of the retina (SLB group).
3,387 (77.3%) participants underwent retinal photography. An
image for grading for AMD in at least one eye was available for
3,304 individuals (75.4%) (image group). 3,274 individuals (74.7%)
had both methods of screening (Figure 1).
Compared to people in the SLB group, those who had images
taken were more likely to be male, younger, urban residents, not
Kikuyu, not diabetic, and not visually impaired (Tables 1 and S1).
A correction factor was necessary because there were significant
differences in the characteristics of the SLB-only group compared
to the image group, and so it was not possible to generalise the
results from the image group to the whole population.
The prevalences of drusen and pigmentary irregularities as
observed on the fundus images, by gender and age, are shown in
Table 2. Note that varying features of AMD, e.g., drusen and
pigmentation, can co-exist in a single eye and in both eyes and
therefore one individual may be listed under more than one AMD
characteristic. However, the prevalence of AMD in the population
is based on the grading of AMD in a person. Drusen were present
in a large proportion of the population. The most common type of
drusen encountered in all ages was small, hard drusen, ,63 mm,
which were present in 59.1% of the study population. Large, soft
drusen, which are considered to be indicative of early AMD, were
present in 9.4% of the population. There were significant age
trends (X2 trend test, p,0.001), with increased prevalence of all
drusen and all pigmentary changes from age 50 y to age 79 y. The
gender difference was less strong, though drusen and pigmentary
changes were more common in women than men. The overall
prevalence of retinal pigment abnormalities was 4.8% (95% CI,
3.7–6.1). Increased pigment was seen more frequently than
depigmentation in all age groups, and prevalence increased from
1.6% in the lowest age groups to 7.2% in those aged 80 y or more.
The difference in prevalence of pigment in men and women was
not significant (p=0.66).
Neovascular AMD was more common (0.9%) than geographic
atrophy (0.5%) (Table 3). There were significant age trends for both,
with geographic atrophy being prevalent in only 0.3% of those in
their 50 s and increasing to 2.0% in those age 80 y and over.
The prevalence of all stages of AMD was lower when SLB
grading was used than when grading was from retinal images
(Table 4). The total prevalence of AMD from SLB was 7.4% (early
AMD, 6.7%, and late AMD, 0.7%), while the prevalence of AMD
by retinal image grading was 12.4% (early AMD, 11.2%, and late
AMD, 1.2%). A smaller proportion of participants were classified
as ungradable by SLB (30; 1.6%) than by retinal image grading
(83; 2.6%). A correction factor of 1.7 for total AMD needs to be
applied for those who did not have retinal imaging (considered the
gold standard) to get the true prevalence estimate of AMD in the
SLB group.
Sensitivity and specificity analysis for the detection of early
AMD and late AMD by SLB grading versus retinal imaging, in
those individuals who had both SLB and image grading available,
showed that SLB grading had poor sensitivity (early, 21.3%, and
late, 36.8%) and good specificity (early, 95.2%, and late, 99.9%).
Macular Degeneration (AMD) in Kenya
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A total of 404 (366 early AMD and 38 late AMD) cases were
confirmed by images, while another 85 cases (75 early AMD and
ten late AMD) were detected in the group that received SLB only.
Combining all cases gives a total of 489 cases, or a prevalence of
11.3% for AMD (435 [10.2%] early AMD and 48 [1.1%] late
AMD) in this population. However, since SLB underdiagnosed
AMD by a factor of 1.7, if this factor is applied to the SLB
prevalences, an adjusted prevalence of 12.7% (11.4% for early
AMD and 1.3% for late AMD) is reached (Table 5).
When extrapolating these data to the entire Kenyan population
based on data from 2007, we estimated that there are 283,900 to
362,800 people over 50 y in Kenya with early AMD and 25,200 to
50,500 with late AMD.
Age/sex-adjusted analyses show that only age and gender were
significantly associated with early AMD, with those affected more
likely to be female and with prevalence increasing with each
decade of age (Table 6).
Modelling age as a continuous variable did not alter the findings
(Table S2).
Age/sex-adjusted analyses showed that only age was signifi-
cantly associated with late AMD, with increased late AMD
prevalence with every decade after 50 y (Table 7). All other
variables showed no association.
Of the 487 people with any grade of AMD (diagnosed by SLB
or retinal images), a total of 137 (28.1%) were visually impaired,
including 12 blind people (2.5%; 95% CI, 1.3–4.8), four with
severe visual impairment (0.8%; 0.3–2.2), and 82 with moderate
visual impairment (16.8%; 13.4–20.9). 350 (71.9%; 7.0–76.4) of
those with AMD had normal vision (Table 8). Among the 669
people with visual impairment in the entire Nakuru study, 137
(20.5%) had features of AMD, either exclusively or in combination
with other pathology.
28 people had visual impairment due to AMD alone (i.e., no
other visually impairing pathology found), a prevalence of 0.6%
(95% CI, 0.4–1.0) for visual impairment from AMD in the
population. 9.9% (seven of 71 people) of blindness in this survey
was attributable to AMD.
Discussion
The prevalences of early and late AMD in this African
population over 50 y of age were 11.2% and 1.2%, respectively.
Very few data exist on the prevalence and causes of AMD in
Africa, and to our knowledge, this is the only population-based
study in Africa using an internationally recognised grading system
and digital retinal photographs. Although data from Rapid
Assessment of Avoidable Blindness surveys exist, these cluster
AMD with other posterior segment eye diseases, and so no direct
comparisons can be made with the findings from this study. A
Nigerian survey used similar methodology, including a population-
based approach and fundus photographs; however, retinal
imaging was performed only in individuals with a visual acuity
Figure 1. AMD study participation chart.
doi:10.1371/journal.pmed.1001393.g001
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Table 1. Demographic characteristics of study participants (n= 4,381).
Attribute
Number (Percent) of Those with
Grading by Retinal Images, n=3,304
Number (Percent of Those with
Only SLB Diagnoses, n=1,038
Age- and Sex-Adjusted
Odds Ratio (95% CI)
Gender
Male 1,629 (49%) 450 (43%) Baseline
Female 1,675 (51%) 588 (57%) 0.8 (0.7–0.9)
Age
50–59 y 1,508 (78.0%) 426 (22.0%) Baseline
60–69 y 997 (77.3%) 292 (22.7%) 1.0 (0.8–1.2)
70–79 y 547 (75.8%) 175 (24.2%) 0.9 (0.8–1.2)
80+ y 252 (63.5%) 145 (36.5%) 0.6 (0.4–0.7)
Environment
Rural 2,143 (69%) 774 (75%) Baseline
Urban 1,161 (31%) 264 (25%) 1.5 (1.3–1.7)
SES
Poorest 783 (24%) 287 (27%) Baseline
2nd quartile 815 (25 %) 267 (26%) 1.0 (0.9–1.2)
3rd quartile 840 (26%) 243 (23%) 1.1 (0.9–1.4)
Least poor 829 (25%) 252 (24%) 1.1 (0.9–1.3)
Tribe
Kikuyu 1,997 (60%) 721 (70%) Baseline
Kalenjin 780 (24%) 211 (20%) 1.3 (1.1–1.6)
Other 527 (16%) 106 (10%) 1.7 (1.3–2.1)
Diabetes
Non-diabetic 3,091 (94%) 947 (92%) Baseline
Diabetic 192 (6%) 86 (8%) 0.7 (0.5–0.9)
Visual impairment
$6/12 2,891 (88%) 820 (79%) Baseline
,6/12 3,973 (12%) 218 (21%) 0.5 (0.4–0.6)
doi:10.1371/journal.pmed.1001393.t001
Table 2. Number and prevalence of features of early AMD (image group) and age-related maculopathy by sex and age (n= 3,304).
Attribute Small Drusen (,63 mm) Large Drusen ($63 mm) Hypopigmentation Hyperpigmentation
N Percent (95% CI) N Percent (95% CI) N Percent (95% CI) N Percent (95% CI)
Total 1,954 59.1 (56.1–62.1) 310 9.4 (8.2–10.7) 79 2.4 (1.7–3.3) 117 3.5 (2.7–4.6)
Age
50–59 y 813 53.9 (50.0–57.8) 52 3.5 (2.6–4.6) 31 2.1 (1.2–3.4) 24 1.6 (0.9–2.7)
60–69 y 603 60.4 (56.4–64.3) 92 9.2 (7.5–11.4) 26 2.6 (1.7–4.1) 41 4.1 (2.8–6.0)
70–79 y 372 68.0 (63.6–72.2) 103 18.8 (15.4–22.9) 17 3.1 (1.8–5.4) 34 6.2 (4.3–8.9)
80+ y 166 66.1 (59.0–72.6) 63 25.1 (20.1–30.9) 5 2.0 (0.7–5.3) 18 7.2 (4.2–12.1)
p-Valuea ,0.001 ,0.001 ,0.001 ,0.001
Gender
Male 889 54.6 (51.0–58.1) 123 7.6 (6.4–8.9) 36 2.2 (1.5–3.2) 45 2.8 (2.0–3.9)
Female 1,065 63.6 (60.0–67.1) 187 11.2 (9.3–13.4) 43 2.6 (1.7–3.9) 72 4.3 (3.1–5.9)
p-Valueb ,0.001 0.002 0.74 0.05
aX2 trend test for age groups.
bX2 trend for sex differences.
doi:10.1371/journal.pmed.1001393.t002
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Table 3. Number and prevalence of features of late AMD (image group) by sex and age (n= 3,304).
Attribute Neovascular AMD GA No Late AMD
N Percent (95% CI) N Percent (95% CI) N Percent (95% CI)
Total 29 0.9 (0.5–1.4) 18 0.5 (0.3–0.9) 3,266 98.9 (98.3–99.2)
Age
50–59 y 5 0.3 (0.1–0.9) 3 0.2 (0.1–0.6) 1,503 99.5(99.0–99.8)
60–69 y 10 1.0 (0.5–2.0) 4 0.4 (0.2–1.1) 987 98.8 (97.8–99.8)
70–79 y 7 1.3 (0.6–2.9) 6 1.1 (0.4–2.8) 540 98.2 (96.3–99.1)
80+ y 7 2.1 (1.1–6.8) 5 2.1 (0.8–4.6) 246 96.4 (92.5–98.3)
p-Valuea ,0.001 ,0.001 ,0.001
Gender
Male 10 0.6 (0.3–1.2) 10 0.6 (0.3–1.2) 1,614 99.1 (95.7–97.5)
Female 19 1.1 (0.7–1.9) 8 0.5 (0.2–0.9) 1,652 98.6 (95.2–97.0)
p-Valuea 0.70 0.80 0.30
aThe features of late AMD, i.e., neovascular changes and geographic atrophy, are not mutually exclusive, so individuals may appear in both columns. The data for late
AMD, and hence for ‘‘no late AMD’’, is person-specific and therefore mutually exclusive. Those with both GA and neovascular AMD are counted in the neovascular AMD
group.
Table 4. Comparison of SLB and image groups.
Variable Prevalence in Image Group Prevalence in Same People by SLB Underdiagnosis Factor for SLB
Number gradable 3,304 3,274
Early AMD 366 (11.1%) 219 (6.7%) 1.7
Late AMD 38 (1.2%) 24 (0.7%) 1.6
Total AMD 404 (12.2%) 243 (7.4%) 1.7
Data are given as number (percentage).
doi:10.1371/journal.pmed.1001393.t004
Table 5. Determination of all AMD cases and adjusted prevalence including diagnosis by SLB.
Terms Early AMD Late AMD Total AMD No AMD
Confirmed by retinal images (A) (n=3,304) 366 38 404 2,900
Confirmed only by SLB (B) (n= 4,312) 75 10 85 953
Total observed cases (n= 4,342) 441 48 489 3853
Prevalence 10.2% 1.1% 11.3% 88.7%
95% CI (9.0–11.5) (0.8–1.6) (10.0–12.7) (87.3–90.0)
Corrected prevalence (A+[B61.7 or 1.6])/3,797 11.4% 1.3% 12.7% 87.4%
doi:10.1371/journal.pmed.1001393.t005
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of #6/12 [26]. In the present study, 75.1% of individuals
identified as having AMD had an acuity of 6/12 or greater.
Only one other prospective study of AMD in Africa was found
in the peer-reviewed literature. A hospital-based study in South
Africa that looked specifically at AMD in Africans was published
in 1978 [31]. The study participants were aged 50 y and older, as
in this study, and were examined by indirect ophthalmoscopy as
well as photography. Higher levels of ‘‘senile macular degenera-
tion’’, as AMD was then termed, were reported than in this study,
affecting 17.4% of participants in the study. It is likely that the
Table 6. Risk factors for early AMD.
Category Risk Factor
Number with
Early AMD Prevalence (95% CI)
Age- and Sex-
Adjusted Odds
Ratio (95% CI)
Demographic factors Age group (years)
50–59 82 5.5% (4.2–7.1) Reference
60–69 115 11.7% (9.8–13.9) 2.3 (1.7–3.1)
70–79 110 20.5% (16.7–24.9) 4.7 (3.5–6.4)
$80 59 24.3% (19.3–30.1) 5.7 (3.9–8.3)
Gender
Female 212 9.5% (7.7–10.6) 1.5 (1.2–1.9)
Male 154 12.8% (10.6–15.5) Reference
Tribe
Kikuyu 244 12.3% (10.3–14.8) Reference
Kalenjin 80 10.4% (8.5–12.8) 0.8 (0.6–1.1)
Other 42 7.8% (5.8–11.2) 0.9 (0.7–1.3)
SES
1st quartile (poorest) 112 14.6% (12.2–17.4) Reference
2nd quartile 102 12.6% (10.0–15.8) 1.0 (0.7–1.3)
3rd quartile 84 10.1% (8.0–12.7) 0.9 (0.7–1.2)
4th quartile (richest) 65 7.9% (5.8–10.8) 0.8 (0.5–1.1)
Systemic factors Body mass index
,25 kg/m2 252 12.2% (10.6–14.0) Reference
Overweight (25–29.9 kg/m2) 78 10.5% (8.3–13.1) 1.0 (0.7–1.3)
Obese ($30.0 kg/m2) 33 7.8% (5.2–11.4) 0.7(0.5–1.0)
Diabetes
Yes 15 7.9% (4.3–14.1) 0.7 (0.4–1.1)
No 350 11.5% (9.9–13.2) Reference
Hypertension
Hypertensive 213 12.8% (10.7–15.2) 1.2 (1.0–1.5)
Non-hypertensive 152 9.7% (8.2–11.4) Reference
Angina grade
None 290 10.8% (8.7–11.9) Reference
Grade 1 55 12.4% (9.3–15.2) 1.2 (0.9–1.7)
Grade 2 20 16.4% (11.5–22.8) 1.7 (1.0–2.9)
Smoking
Current 21 7.8% (5.3–11.2) 0.8 (0.5–1.4)
Former 77 10.5% (8.5–12.9) 1.0 (0.7–1.4)
Never 267 11.9% (10.1–14.0) Reference
Alcohol
Current 68 11.6% (9.0–14.7) 1.3 (0.9–1.9)
Former 160 11.3% (9.6–13.2) 1.0 (0.8–1.3)
Never 137 11.1% (8.7–14.1) Reference
Ocular features Cataract surgery
Yes 26 15.2% (10.6–21.3) 0.9 (0.5–1.3)
No 339 11.0% (9.5–12.7) Reference
doi:10.1371/journal.pmed.1001393.t006
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hospital population sampled was not representative of the general
population, as enrolled participants had attended the hospital eye
clinic of their own volition and therefore were more likely to have
had symptomatic vision loss than the general population.
Typically, the demographic of individuals attending a hospital
clinic also differs from the general population in terms of SES and
life expectancy. No population-based studies specifically reporting
AMD in Africa have been published, to our knowledge.
The prevalence of AMD in this study was also lower than that in
a study in the Caribbean, where a 28.7% prevalence of AMD was
found [32]. In general, the prevalences in our study are similar to
or higher than those documented for Hispanic and Asian
populations (range 7.1%–13.6%) [13,33–36], but lower than
those found in white populations (range 9.3%–43.1%) [36–39].
Direct comparison between studies is not appropriate because of
the different grading systems and diagnostic techniques used.
A strength of this study was the high response rate (88.1%).
Despite the sophisticated equipment used in the examinations,
people were not transported to a fixed examination site, but
instead the examination site moved from cluster to cluster. A large,
representative population-based sample was examined by SLB and
retinal imaging. Another strength of the study is that the same
experienced ophthalmologist (W. M.) was present throughout the
study and examined all participants. However, a lack of stable
electricity supply resulted in the number of people who had retinal
images being reduced in some clusters.
A limitation of the study was our not having been able to obtain
retinal images for all study participants. This is in large part due to
the logistical constraints of performing electricity-dependent
examinations in a setting where electricity supply cannot be
guaranteed. Univariable analyses comparing those with gradable
images (n=3,304) and those without (n=83) found significant
differences. Those with no gradable images were more likely to be
older, have poor vision, and have a cataract, thus the prevalence
for this population may be slightly underestimated. The difference
between the groups is likely due to a lack of stable electricity supply
in the more rural clusters, where participants were demograph-
ically different.
When disease estimates using both methods were compared,
SLB was found to have consistently under-diagnosed AMD. An
analysis of the false negatives for late AMD revealed that lesions
were noted but were not called neovascular AMD; instead they
Table 7. Risk factors for late AMD.
Category Risk Factor
Number with Late
AMD Prevalence (95% CI)
Age- and Sex- Adjusted
Odds Ratio (95% CI)
Demographic factors Age group (years)
50–59 7 0.5% (0.2–1.0) Reference
60–69 12 1.2% (0.7–2.2) 2.8 (1.1–7.3)
70–79 10 1.8% (0.9–3.7) 5.1 (1.9–13.5)
$80 9 3.6% (1.7–7.5) 10.4 (3.8–28.2)
Gender
Female 23 1.0% (0.6–1.7) 1.8 (0.9–3.4)
Male 15 1.6% (1.0–2.4) Reference
Tribe
Kikuyu 20 1.1% (0.6–2.1) Reference
Kalenjin 11 1.5% (0.8–3.1) 1.4 (0.7–3.0)
Other 7 1.4% (0.7–3.2) 2.2 (0.9–5.5)
Environment
Rural 31 1.6% (1.0–2.6) Reference
Urban 7 0.7% (0.3–1.45) 0.6 (0.2–1.3)
Systemic factors Cholesterol
Low 31 1.1% (0.7–1.8) Reference
High 4 3.7% (1.4–9.6) 3.0 (1.0–8.9)
Smoking
Current 4 1.6% (0.6–4.1) 2.2 (0.7–6.6)
Former 6 0.9% (0.4–2.0) 1.0 (0.4–2.7)
Never 28 1.4% (0.9–2.1) Reference
Alcohol
Current 7 1.3% (0.6–3.0) 0.9 (0.3–2.4)
Former 12 0.9% (0.5–1.8) 0.5 (0.2–1.1)
Never 19 1.7% (1.1–2.7) Reference
Ocular features Cataract surgery
Yes 6 4.0% (1.9–8.1) 2.1 (0.8–5.2)
No 32 1.2% (0.7–1.8) Reference
doi:10.1371/journal.pmed.1001393.t007
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were called macular scars. This may be a reflection of general
practice in Africa, where it is often repeated in residency courses
that ‘‘wet AMD’’ does not occur in Africans, as has been asserted
in several studies [40,41]. This leads to late AMD being placed far
down in the differential diagnosis for macular scars.
There was also discrepancy in identifying pigmentary lesions of
early AMD. Retinal imaging identified many more hyperpig-
mented changes at the macula than did SLB. There are large
natural variations in retinal pigmentation, resulting in colour
differences between individuals. Such variation can tend to mask
the more subtle variation between the important lesion types [42].
Studies have shown that the macular pigment density in other
population groups is significantly lower than in African individuals
[43]. The study ophthalmologist’s perception of what constitutes
increased pigment and what is normal background pigment in an
African eye, in comparison to the reading centre’s criteria, may
have led to differences in classification.
Vision is measured based on the person’s better eye, whereas
AMD affects both eyes, and therefore a disparity between late
AMD and poor vision can be seen. For example, there were 38
participants in the present study with late AMD, but only 16 with
AMD and a visual acuity ,6/60.
Disease subgroups included limited sample sizes, particularly for
advanced AMD and blindness, which should be noted when
interpreting the results.
Data collection began in 2007 and was based on electoral roll
data from 2006. The population demographic is likely to have
changed in the time to publication, and given population growth
and increased survival, the estimated national prevalence of AMD
could underestimate current prevalence.
Of note, location information collected from participants in this
study will allow for incidence studies to be carried out in the
future, thus providing new insights into the natural progression
and incidence of AMD in this population.
Conclusion
Despite the long held belief that AMD is not a public health
concern in Africa, this study provides evidence not only that is
AMD as prevalent as in some other world regions (12.4% in this
population), but also that it is an important problem contributing
to both visual impairment and blindness in Africa. A total of 9.9%
of blindness in this survey was attributable to AMD.
New therapeutic strategies have increased the available treatment
options and improved prognostic perspectives for AMD in low-
income countries [44]. However, these emerging treatments for
AMD are largely unavailable in Kenya and most of Africa. When
they become available, cost may be a major barrier towards
accessing the treatment. Recent evidence suggests that bevacizumab
is both effective and relatively affordable [45–47], but the
infrastructure required to deliver an adequate AMD service,
including the use of expensive optical coherence tomography
machines, may be prohibitive. It is estimated that over 12 million
people in Africa have low vision [48], and AMD is certainly a major
contributor. Low vision services remain a hugely neglected area of
care on the African continent; strengthening these services might be
a cost-effective use of limited resources in the interim period. There
is a need to train African-based ophthalmologists to improve
recognition and treatment of AMD, particularly neovascular AMD,
and a need for research to support the development of treatment
programmes that are affordable and deliverable in Africa.
Table 8. Visual acuity in those with AMD.
Visual Acuity
All AMD from
Retinal Images
All AMD from
SLB Only Total AMD No AMD Total
Normal ($6/12)
Number 302 48 350 3362 3,712
Percent 75.1% 56.5% 71.9% 86.3% 84.7%
95% CI (70.1–79.5) (44.3–67.9) (67.0–76.4) (84.6–87.9) (82.9–86.4)
Mild VI (,6/12–6/18)
Number 23 16 39 185 224
Percent 5.7% 18.8% 8.0% 4.8% 5.1%
95% CI (3.9–8.3) (12.5–27.1) (6.0–10.6) (4.0–5.7) (4.3–6.1)
Moderate VI (,6/18–6/60)
Number 66 16 82 274 356
Percent 16.4% 18.8% 16.8% 7.0% 8.1%
95% CI (12.7–21.0) (11.9–28.5) (13.4–20.9) (6.2–8.0) (7.2–9.2)
Severe VI (,6/60–3/60)
Number 1 3 4 14 18
Percent 0.3% 3.5% 0.8% 0.4% 0.4%
95% CI (0.03–1.2) (1.2–9.8) (0.3–2.2) (0.2–6.4) (0.3–0.7)
Blind (,3/60)
Number 10 2 12 59 71
Percent 2.5% 2.4% 2.5% 1.5% 1.6%
95% CI (1.2–5.0) (0.6–9.2) (1.3–4.8) (1.2–2.0) (1.2–2.1)
Total Number (Percent) 402 (100%) 85 (100%) 487 (100%) 3,894 (100%) 4,381 (100%)
VI, visual impairment.
doi:10.1371/journal.pmed.1001393.t008
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Editors’ Summary
Background. Worldwide, 39 million people are blind, and
246 million people (mainly living in developing countries)
have moderate or severe visual impairment. The third
leading global cause of blindness (after cataracts and
glaucoma) is age-related macular degeneration (AMD). This
group of conditions is characterized by lesions in the macular
(central) region of the retina, the tissue at the back of the eye
that converts light into electrical messages and sends them
to the brain. AMD, which affects older people, destroys the
sharp central vision that is needed for reading or driving,
leaving only dim, blurred images or a black hole at the center
of vision. AMD can be diagnosed by examining digital
photographs of the retina or by examining the retina directly
using a special magnifying lens (slit lamp biomicroscopy).
There is no cure for AMD, although injections into the eye of
certain drugs, such as bevacizumab, that block the activity of
vascular endothelial growth factor can slow the rate of vision
loss caused by some forms of AMD.
Why Was This Study Done? Most investigations of the
prevalence (the proportion of a population with a disease) of
AMD and of risk factors for AMD have studied people with
European or Asian ancestry. Very little is known about AMD
in African populations, and the data that are available mainly
come from African populations living outside Africa. It is
important to know whether AMD is an important cause of
visual impairment and blindness in Africa, so that informed
decisions can be made about the need for AMD programs in
African countries. In this cross-sectional population-based
study, the researchers investigate the prevalence of AMD
among people aged 50 years or older living in Nakuru
District (an ethnically diverse region of Kenya) and look for
predictors of AMD in this population. In a cross-sectional
population-based study, researchers observe a representa-
tive subset of a population at a single time point.
What Did the Researchers Do and Find? The researchers
randomly selected 100 clusters of 50 people aged 50 years or
older for their study. Between January 2007 and November
2008, study participants had a comprehensive eye examina-
tion and completed a standardized interview that included
questions about their age, gender, other demographic
details, medical history, and exposure to possible risk factors
for AMD. Based on digital retinal images, the prevalences of
early and late AMD among the study population were 11.2%
and 1.2%, respectively. The prevalences of early and late
AMD judged by slit lamp biomicroscopy were 6.7% and
0.7%, respectively. After controlling for age, women had a
higher prevalence of both early and late AMD than men. The
overall prevalence of AMD rose with age: compared to the
youngest age group, the oldest age group had a three-fold
higher risk of developing late AMD. Of the people with any
grade of AMD, 25.6% had some visual impairment and 2.5%
were blind. Overall, 9.9% of the blindness seen in the study
was attributable to AMD.
What Do These Findings Mean? These findings identify
AMD as an important cause of visual impairment and
blindness in Nakuru District, Kenya. Extrapolation of these
findings to the whole of Kenya suggests that 283,900 to
362,800 Kenyans had early AMD and 25,200 to 50,500 had
late AMD in 2007. The accuracy of these findings is limited by
the inability to obtain digital retinal images from all the
participants (often because of electricity failures) and by
other aspects of the study design. Moreover, because the
methodology used in this study differed from some other
studies of AMD, the prevalence of AMD reported here cannot
be compared directly to those found in other studies.
Nevertheless, these findings have several important implica-
tions. In particular, although recent evidence suggests that
bevacizumab is likely to be both effective and affordable in
Africa, the infrastructure required to deliver an adequate
AMD service is currently prohibitively expensive in most
African countries. Thus, these findings suggest that it is
essential that research is undertaken to support the
development of AMD treatment programs that are afford-
able and deliverable in Africa, and that low vision resources
are provided for individuals with vision impairment.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001393.
N The US National Eye Institute provides detailed information
about age-related macular degeneration
N The UK National Health Service Choices website also
provides information about age-related macular
degeneration, including personal stories about the condi-
tion
N The UK Royal National Institute of Blind People has
information on age-related macular degeneration, includ-
ing a video of a person describing their experiences of the
condition
N AMD Alliance International provides written and audio
information in several languages about age-related mac-
ular degeneration, including a large selection of personal
stories; the Macular Degeneration Partnership also pro-
vides information about age-related macular degeneration,
including a simulation of the condition
N MedlinePlus has links to additional resources about age-
related macular degeneration (in English and Spanish)
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